Tuberc Respir Dis.  2002 Feb;52(2):128-136. 10.4046/trd.2002.52.2.128.

Pharmacokinetics of ofloxacin in Patients with Multidrug-Resistant Tuberculosis

• Park SK
• Yoon YR
• Lee WC
• Jun HM
• Shon JH
• Kim KA
• Park JY
• Shin JG

• KMID: 2050261
• DOI: http://doi.org/10.4046/trd.2002.52.2.128

Abstract

BACKGROUND: There are few studies that have reported on the pharmacokinetic(PK) disposition of fluoroquinolones in patients with multi-drug resistant tuberculosis(MDR-Tb), even though fluoroquinolones are frequentl y co-prescribed to those patients. In this study, the PK disposition of ofloxacin, a fluoroquinolone, was evaluated in patients with MDR-Tb.
METHODS
Twenty patients with MDR-Tb were given 2nd line Tb drugs including ofloxacin (300mg twice a day), prothionamide, cycloserine, para-aminosalicylic acid, kanamycin, and streptomycin. The patients were grouped according to their body mass index(BMI) as an index of emaciation (group A: 18.5RESULTS
The AUC of ofloxacin in group B was greater than that in group A (31.4+/-8.9micro gram/ml.h vs. 24.1+/-6.2micro gram/ml.h)(Check the symbols),(p<0.05). The total clearance(CI/F) of ofloxacin was 0.16+/-0.03 l/h/kg in group A, and 0.14+/-0.03 l/h/kg in group B. The half-lives of ofloxacin in two groups were similar (group A: 5.3+/-0.8 hours, group B: 5.7+/-0.9 hours). In addition, the other PK parameters in two groups were also similar.
CONCLUSIONS
The pharmacokinetics of ofloxacin in patients with MDR-Tb appears to be comparable with those of normal subjects, and the extent of emaciation appears to have an influence on the pharmacokinetics of ofloxacin in chronic debilitated MDR-Tb patients.

Keyword

MDR-Tb; Ofloxacin; Pharmacokinetics; BMI

MeSH Terms

Aminosalicylic Acid
Area Under Curve
Chromatography, High Pressure Liquid
Cycloserine
Emaciation
Fluoroquinolones
Humans
Kanamycin
Ofloxacin*
Pharmacokinetics*
Prothionamide
Streptomycin
Tuberculosis, Multidrug-Resistant*
Aminosalicylic Acid
Cycloserine
Fluoroquinolones
Kanamycin
Ofloxacin
Prothionamide
Streptomycin